HUTCHMED (China) Limited
HUTCHMED (China) Limited (HCM) Stock Competitors & Peer Comparison
See (HCM) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HCM | $12.51 | -1.42% | 2.2B | 4.72 | $2.65 | N/A |
| TAK | $16.61 | -0.12% | 52.5B | 43.70 | $0.38 | +3.73% |
| TEVA | $34.29 | -2.89% | 39.9B | 25.21 | $1.36 | N/A |
| HLN | $8.96 | +0.56% | 39.8B | 17.92 | $0.50 | +2.16% |
| VTRS | $16.48 | -4.52% | 19.2B | -54.93 | -$0.30 | +2.91% |
| RGC | $28.58 | +6.21% | 14.1B | -2858.00 | -$0.01 | N/A |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| RDY | $13.61 | +0.89% | 11.3B | 25.68 | $0.53 | +0.67% |
| ELAN | $19.86 | -8.23% | 9.9B | -39.71 | -$0.50 | N/A |
Stock Comparison
HCM vs TAK Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, TAK has a market cap of 52.5B. Regarding current trading prices, HCM is priced at $12.51, while TAK trades at $16.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas TAK's P/E ratio is 43.70. In terms of profitability, HCM's ROE is +0.41%, compared to TAK's ROE of +0.03%. Regarding short-term risk, HCM is more volatile compared to TAK. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check TAK's competition here
HCM vs TEVA Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, TEVA has a market cap of 39.9B. Regarding current trading prices, HCM is priced at $12.51, while TEVA trades at $34.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas TEVA's P/E ratio is 25.21. In terms of profitability, HCM's ROE is +0.41%, compared to TEVA's ROE of +0.21%. Regarding short-term risk, HCM is less volatile compared to TEVA. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check TEVA's competition here
HCM vs HLN Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, HLN has a market cap of 39.8B. Regarding current trading prices, HCM is priced at $12.51, while HLN trades at $8.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas HLN's P/E ratio is 17.92. In terms of profitability, HCM's ROE is +0.41%, compared to HLN's ROE of +0.17%. Regarding short-term risk, HCM is more volatile compared to HLN. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check HLN's competition here
HCM vs VTRS Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, VTRS has a market cap of 19.2B. Regarding current trading prices, HCM is priced at $12.51, while VTRS trades at $16.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas VTRS's P/E ratio is -54.93. In terms of profitability, HCM's ROE is +0.41%, compared to VTRS's ROE of -0.02%. Regarding short-term risk, HCM is less volatile compared to VTRS. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check VTRS's competition here
HCM vs RGC Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, RGC has a market cap of 14.1B. Regarding current trading prices, HCM is priced at $12.51, while RGC trades at $28.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas RGC's P/E ratio is -2858.00. In terms of profitability, HCM's ROE is +0.41%, compared to RGC's ROE of -2.32%. Regarding short-term risk, HCM is less volatile compared to RGC. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check RGC's competition here
HCM vs ITCI Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, HCM is priced at $12.51, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas ITCI's P/E ratio is -180.64. In terms of profitability, HCM's ROE is +0.41%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, HCM is more volatile compared to ITCI. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check ITCI's competition here
HCM vs CTLT Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, HCM is priced at $12.51, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas CTLT's P/E ratio is -27.84. In terms of profitability, HCM's ROE is +0.41%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, HCM is more volatile compared to CTLT. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check CTLT's competition here
HCM vs RDY Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, RDY has a market cap of 11.3B. Regarding current trading prices, HCM is priced at $12.51, while RDY trades at $13.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas RDY's P/E ratio is 25.68. In terms of profitability, HCM's ROE is +0.41%, compared to RDY's ROE of +0.12%. Regarding short-term risk, HCM is less volatile compared to RDY. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check RDY's competition here
HCM vs ELAN Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, ELAN has a market cap of 9.9B. Regarding current trading prices, HCM is priced at $12.51, while ELAN trades at $19.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas ELAN's P/E ratio is -39.71. In terms of profitability, HCM's ROE is +0.41%, compared to ELAN's ROE of -0.04%. Regarding short-term risk, HCM is less volatile compared to ELAN. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check ELAN's competition here
HCM vs LNTH Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, LNTH has a market cap of 6.1B. Regarding current trading prices, HCM is priced at $12.51, while LNTH trades at $93.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas LNTH's P/E ratio is 22.41. In terms of profitability, HCM's ROE is +0.41%, compared to LNTH's ROE of +0.24%. Regarding short-term risk, HCM is less volatile compared to LNTH. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check LNTH's competition here
HCM vs INDV Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, INDV has a market cap of 4.6B. Regarding current trading prices, HCM is priced at $12.51, while INDV trades at $36.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas INDV's P/E ratio is 18.85. In terms of profitability, HCM's ROE is +0.41%, compared to INDV's ROE of -1.42%. Regarding short-term risk, HCM is less volatile compared to INDV. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check INDV's competition here
HCM vs AMRX Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, AMRX has a market cap of 3.8B. Regarding current trading prices, HCM is priced at $12.51, while AMRX trades at $11.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas AMRX's P/E ratio is 32.24. In terms of profitability, HCM's ROE is +0.41%, compared to AMRX's ROE of -1.45%. Regarding short-term risk, HCM is less volatile compared to AMRX. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check AMRX's competition here
HCM vs SUPN Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, SUPN has a market cap of 2.9B. Regarding current trading prices, HCM is priced at $12.51, while SUPN trades at $49.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas SUPN's P/E ratio is -96.92. In terms of profitability, HCM's ROE is +0.41%, compared to SUPN's ROE of -0.03%. Regarding short-term risk, HCM is less volatile compared to SUPN. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check SUPN's competition here
HCM vs DCPH Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, HCM is priced at $12.51, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas DCPH's P/E ratio is -11.58. In terms of profitability, HCM's ROE is +0.41%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, HCM is more volatile compared to DCPH. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check DCPH's competition here
HCM vs AVDL Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, HCM is priced at $12.51, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, HCM's ROE is +0.41%, compared to AVDL's ROE of -0.00%. Regarding short-term risk, HCM is more volatile compared to AVDL. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check AVDL's competition here
HCM vs BHC Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, BHC has a market cap of 2B. Regarding current trading prices, HCM is priced at $12.51, while BHC trades at $5.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas BHC's P/E ratio is -1.68. In terms of profitability, HCM's ROE is +0.41%, compared to BHC's ROE of +1.21%. Regarding short-term risk, HCM is less volatile compared to BHC. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check BHC's competition here
HCM vs EMBCV Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, HCM is priced at $12.51, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas EMBCV's P/E ratio is N/A. In terms of profitability, HCM's ROE is +0.41%, compared to EMBCV's ROE of -0.23%. Regarding short-term risk, HCM is less volatile compared to EMBCV. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check EMBCV's competition here
HCM vs DVAX Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, HCM is priced at $12.51, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas DVAX's P/E ratio is -41.89. In terms of profitability, HCM's ROE is +0.41%, compared to DVAX's ROE of -0.08%. Regarding short-term risk, HCM is more volatile compared to DVAX. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check DVAX's competition here
HCM vs ANIP Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, ANIP has a market cap of 1.8B. Regarding current trading prices, HCM is priced at $12.51, while ANIP trades at $78.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas ANIP's P/E ratio is 19.95. In terms of profitability, HCM's ROE is +0.41%, compared to ANIP's ROE of +0.17%. Regarding short-term risk, HCM is less volatile compared to ANIP. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check ANIP's competition here
HCM vs TARO Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, HCM is priced at $12.51, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas TARO's P/E ratio is 30.05. In terms of profitability, HCM's ROE is +0.41%, compared to TARO's ROE of +0.03%. Regarding short-term risk, HCM is more volatile compared to TARO. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check TARO's competition here
HCM vs PRGO Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, PRGO has a market cap of 1.5B. Regarding current trading prices, HCM is priced at $12.51, while PRGO trades at $10.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas PRGO's P/E ratio is -0.82. In terms of profitability, HCM's ROE is +0.41%, compared to PRGO's ROE of -0.51%. Regarding short-term risk, HCM is less volatile compared to PRGO. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check PRGO's competition here
HCM vs PAHC Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, HCM is priced at $12.51, while PAHC trades at $34.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas PAHC's P/E ratio is 14.75. In terms of profitability, HCM's ROE is +0.41%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, HCM is less volatile compared to PAHC. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check PAHC's competition here
HCM vs HROW Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, HROW has a market cap of 1.2B. Regarding current trading prices, HCM is priced at $12.51, while HROW trades at $31.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas HROW's P/E ratio is -82.13. In terms of profitability, HCM's ROE is +0.41%, compared to HROW's ROE of -0.34%. Regarding short-term risk, HCM is less volatile compared to HROW. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check HROW's competition here
HCM vs COLL Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, COLL has a market cap of 1.1B. Regarding current trading prices, HCM is priced at $12.51, while COLL trades at $33.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas COLL's P/E ratio is 16.40. In terms of profitability, HCM's ROE is +0.41%, compared to COLL's ROE of +0.27%. Regarding short-term risk, HCM is less volatile compared to COLL. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check COLL's competition here
HCM vs ALVO Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, ALVO has a market cap of 1B. Regarding current trading prices, HCM is priced at $12.51, while ALVO trades at $3.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas ALVO's P/E ratio is 33.10. In terms of profitability, HCM's ROE is +0.41%, compared to ALVO's ROE of -0.12%. Regarding short-term risk, HCM is less volatile compared to ALVO. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check ALVO's competition here
HCM vs CRON Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, CRON has a market cap of 982.7M. Regarding current trading prices, HCM is priced at $12.51, while CRON trades at $2.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas CRON's P/E ratio is -131.50. In terms of profitability, HCM's ROE is +0.41%, compared to CRON's ROE of -0.00%. Regarding short-term risk, HCM is less volatile compared to CRON. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check CRON's competition here
HCM vs EVO Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, EVO has a market cap of 959M. Regarding current trading prices, HCM is priced at $12.51, while EVO trades at $2.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas EVO's P/E ratio is -4.22. In terms of profitability, HCM's ROE is +0.41%, compared to EVO's ROE of -0.24%. Regarding short-term risk, HCM is less volatile compared to EVO. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check EVO's competition here
HCM vs PETQ Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, HCM is priced at $12.51, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas PETQ's P/E ratio is 83.73. In terms of profitability, HCM's ROE is +0.41%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, HCM is more volatile compared to PETQ. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check PETQ's competition here
HCM vs PCRX Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, PCRX has a market cap of 890.5M. Regarding current trading prices, HCM is priced at $12.51, while PCRX trades at $22.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas PCRX's P/E ratio is 174.15. In terms of profitability, HCM's ROE is +0.41%, compared to PCRX's ROE of +0.01%. Regarding short-term risk, HCM is less volatile compared to PCRX. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check PCRX's competition here
HCM vs AMPH Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, AMPH has a market cap of 743.8M. Regarding current trading prices, HCM is priced at $12.51, while AMPH trades at $16.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas AMPH's P/E ratio is 10.16. In terms of profitability, HCM's ROE is +0.41%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, HCM is less volatile compared to AMPH. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check AMPH's competition here
HCM vs TLRY Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, TLRY has a market cap of 634.5M. Regarding current trading prices, HCM is priced at $12.51, while TLRY trades at $5.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas TLRY's P/E ratio is -0.36. In terms of profitability, HCM's ROE is +0.41%, compared to TLRY's ROE of -0.93%. Regarding short-term risk, HCM is less volatile compared to TLRY. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check TLRY's competition here
HCM vs IRWD Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, IRWD has a market cap of 589.3M. Regarding current trading prices, HCM is priced at $12.51, while IRWD trades at $3.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas IRWD's P/E ratio is 5.77. In terms of profitability, HCM's ROE is +0.41%, compared to IRWD's ROE of -0.39%. Regarding short-term risk, HCM is less volatile compared to IRWD. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check IRWD's competition here
HCM vs BDSI Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, HCM is priced at $12.51, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas BDSI's P/E ratio is 6.82. In terms of profitability, HCM's ROE is +0.41%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, HCM is more volatile compared to BDSI. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check BDSI's competition here
HCM vs KMDA Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, KMDA has a market cap of 444.8M. Regarding current trading prices, HCM is priced at $12.51, while KMDA trades at $7.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas KMDA's P/E ratio is 22.03. In terms of profitability, HCM's ROE is +0.41%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, HCM is less volatile compared to KMDA. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check KMDA's competition here
HCM vs CGC Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, CGC has a market cap of 442.9M. Regarding current trading prices, HCM is priced at $12.51, while CGC trades at $1.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas CGC's P/E ratio is -0.76. In terms of profitability, HCM's ROE is +0.41%, compared to CGC's ROE of -0.53%. Regarding short-term risk, HCM is less volatile compared to CGC. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check CGC's competition here
HCM vs EOLS Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, EOLS has a market cap of 428.1M. Regarding current trading prices, HCM is priced at $12.51, while EOLS trades at $6.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas EOLS's P/E ratio is -9.85. In terms of profitability, HCM's ROE is +0.41%, compared to EOLS's ROE of +1.75%. Regarding short-term risk, HCM is less volatile compared to EOLS. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check EOLS's competition here
HCM vs AQST Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, AQST has a market cap of 414.1M. Regarding current trading prices, HCM is priced at $12.51, while AQST trades at $4.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas AQST's P/E ratio is -6.84. In terms of profitability, HCM's ROE is +0.41%, compared to AQST's ROE of +1.91%. Regarding short-term risk, HCM is less volatile compared to AQST. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check AQST's competition here
HCM vs SNDL Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, SNDL has a market cap of 370.7M. Regarding current trading prices, HCM is priced at $12.51, while SNDL trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas SNDL's P/E ratio is -47.67. In terms of profitability, HCM's ROE is +0.41%, compared to SNDL's ROE of -0.01%. Regarding short-term risk, HCM is less volatile compared to SNDL. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check SNDL's competition here
HCM vs ORGO Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, ORGO has a market cap of 310.1M. Regarding current trading prices, HCM is priced at $12.51, while ORGO trades at $2.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas ORGO's P/E ratio is -20.08. In terms of profitability, HCM's ROE is +0.41%, compared to ORGO's ROE of -0.00%. Regarding short-term risk, HCM is less volatile compared to ORGO. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check ORGO's competition here
HCM vs ALIM Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, HCM is priced at $12.51, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas ALIM's P/E ratio is 5.28. In terms of profitability, HCM's ROE is +0.41%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, HCM is more volatile compared to ALIM. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check ALIM's competition here
HCM vs SIGA Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, SIGA has a market cap of 299.1M. Regarding current trading prices, HCM is priced at $12.51, while SIGA trades at $4.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas SIGA's P/E ratio is 14.89. In terms of profitability, HCM's ROE is +0.41%, compared to SIGA's ROE of +0.11%. Regarding short-term risk, HCM is less volatile compared to SIGA. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check SIGA's competition here
HCM vs LNDC Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, HCM is priced at $12.51, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas LNDC's P/E ratio is -4.04. In terms of profitability, HCM's ROE is +0.41%, compared to LNDC's ROE of -9.05%. Regarding short-term risk, HCM is less volatile compared to LNDC. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check LNDC's competition here
HCM vs TYHT Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, HCM is priced at $12.51, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas TYHT's P/E ratio is -1.61. In terms of profitability, HCM's ROE is +0.41%, compared to TYHT's ROE of -0.65%. Regarding short-term risk, HCM is less volatile compared to TYHT. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check TYHT's competition here
HCM vs ACB Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, ACB has a market cap of 188.3M. Regarding current trading prices, HCM is priced at $12.51, while ACB trades at $3.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas ACB's P/E ratio is -3.05. In terms of profitability, HCM's ROE is +0.41%, compared to ACB's ROE of -0.08%. Regarding short-term risk, HCM is less volatile compared to ACB. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check ACB's competition here
HCM vs TKNO Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, TKNO has a market cap of 188.2M. Regarding current trading prices, HCM is priced at $12.51, while TKNO trades at $3.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas TKNO's P/E ratio is -11.32. In terms of profitability, HCM's ROE is +0.41%, compared to TKNO's ROE of -0.24%. Regarding short-term risk, HCM is less volatile compared to TKNO. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check TKNO's competition here
HCM vs EMBC Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, EMBC has a market cap of 186.3M. Regarding current trading prices, HCM is priced at $12.51, while EMBC trades at $3.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas EMBC's P/E ratio is 1.64. In terms of profitability, HCM's ROE is +0.41%, compared to EMBC's ROE of -0.17%. Regarding short-term risk, HCM is less volatile compared to EMBC. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check EMBC's competition here
HCM vs REPH Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, HCM is priced at $12.51, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas REPH's P/E ratio is -8.04. In terms of profitability, HCM's ROE is +0.41%, compared to REPH's ROE of -0.22%. Regarding short-term risk, HCM is less volatile compared to REPH. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check REPH's competition here
HCM vs DERM Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, DERM has a market cap of 174.2M. Regarding current trading prices, HCM is priced at $12.51, while DERM trades at $6.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas DERM's P/E ratio is -17.11. In terms of profitability, HCM's ROE is +0.41%, compared to DERM's ROE of -0.36%. Regarding short-term risk, HCM is less volatile compared to DERM. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check DERM's competition here
HCM vs LFCR Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, LFCR has a market cap of 165M. Regarding current trading prices, HCM is priced at $12.51, while LFCR trades at $4.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas LFCR's P/E ratio is -3.46. In terms of profitability, HCM's ROE is +0.41%, compared to LFCR's ROE of -1.47%. Regarding short-term risk, HCM is less volatile compared to LFCR. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check LFCR's competition here
HCM vs THTX Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, HCM is priced at $12.51, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas THTX's P/E ratio is -17.84. In terms of profitability, HCM's ROE is +0.41%, compared to THTX's ROE of +0.47%. Regarding short-term risk, HCM is more volatile compared to THTX. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check THTX's competition here
HCM vs ASRT Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, ASRT has a market cap of 150.7M. Regarding current trading prices, HCM is priced at $12.51, while ASRT trades at $23.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas ASRT's P/E ratio is -4.20. In terms of profitability, HCM's ROE is +0.41%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, HCM is more volatile compared to ASRT. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check ASRT's competition here
HCM vs CRDL Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, CRDL has a market cap of 147.4M. Regarding current trading prices, HCM is priced at $12.51, while CRDL trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas CRDL's P/E ratio is -4.55. In terms of profitability, HCM's ROE is +0.41%, compared to CRDL's ROE of -2.29%. Regarding short-term risk, HCM is less volatile compared to CRDL. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check CRDL's competition here
HCM vs OGI Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, OGI has a market cap of 145.9M. Regarding current trading prices, HCM is priced at $12.51, while OGI trades at $1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas OGI's P/E ratio is 9.73. In terms of profitability, HCM's ROE is +0.41%, compared to OGI's ROE of -0.07%. Regarding short-term risk, HCM is less volatile compared to OGI. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check OGI's competition here
HCM vs SCTL Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, HCM is priced at $12.51, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas SCTL's P/E ratio is -7.86. In terms of profitability, HCM's ROE is +0.41%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, HCM is more volatile compared to SCTL. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check SCTL's competition here
HCM vs PROC Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, HCM is priced at $12.51, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas PROC's P/E ratio is 1.53. In terms of profitability, HCM's ROE is +0.41%, compared to PROC's ROE of -2.22%. Regarding short-term risk, HCM is more volatile compared to PROC. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check PROC's competition here
HCM vs OPTN Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, HCM is priced at $12.51, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas OPTN's P/E ratio is -4.42. In terms of profitability, HCM's ROE is +0.41%, compared to OPTN's ROE of +0.45%. Regarding short-term risk, HCM is more volatile compared to OPTN. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check OPTN's competition here
HCM vs ZOM Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, HCM is priced at $12.51, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas ZOM's P/E ratio is -1.62. In terms of profitability, HCM's ROE is +0.41%, compared to ZOM's ROE of -0.19%. Regarding short-term risk, HCM is less volatile compared to ZOM. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check ZOM's competition here
HCM vs GRVI Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, HCM is priced at $12.51, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas GRVI's P/E ratio is 26.05. In terms of profitability, HCM's ROE is +0.41%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, HCM is less volatile compared to GRVI. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check GRVI's competition here
HCM vs CPIX Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, CPIX has a market cap of 82M. Regarding current trading prices, HCM is priced at $12.51, while CPIX trades at $5.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas CPIX's P/E ratio is -11.16. In terms of profitability, HCM's ROE is +0.41%, compared to CPIX's ROE of -0.29%. Regarding short-term risk, HCM is less volatile compared to CPIX. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check CPIX's competition here
HCM vs ZYNE Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, HCM is priced at $12.51, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, HCM's ROE is +0.41%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, HCM is less volatile compared to ZYNE. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check ZYNE's competition here
HCM vs BGM Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, BGM has a market cap of 69M. Regarding current trading prices, HCM is priced at $12.51, while BGM trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas BGM's P/E ratio is -1.19. In terms of profitability, HCM's ROE is +0.41%, compared to BGM's ROE of -0.03%. Regarding short-term risk, HCM is less volatile compared to BGM. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check BGM's competition here
HCM vs SSIC Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, HCM is priced at $12.51, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas SSIC's P/E ratio is 11.93. In terms of profitability, HCM's ROE is +0.41%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, HCM is less volatile compared to SSIC. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check SSIC's competition here
HCM vs ALVOW Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, ALVOW has a market cap of 62.4M. Regarding current trading prices, HCM is priced at $12.51, while ALVOW trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas ALVOW's P/E ratio is N/A. In terms of profitability, HCM's ROE is +0.41%, compared to ALVOW's ROE of -0.12%. Regarding short-term risk, HCM is less volatile compared to ALVOW. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check ALVOW's competition here
HCM vs VLNS Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, HCM is priced at $12.51, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas VLNS's P/E ratio is -1.03. In terms of profitability, HCM's ROE is +0.41%, compared to VLNS's ROE of N/A. Regarding short-term risk, HCM is less volatile compared to VLNS. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check VLNS's competition here
HCM vs DRRX Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, HCM is priced at $12.51, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas DRRX's P/E ratio is -4.44. In terms of profitability, HCM's ROE is +0.41%, compared to DRRX's ROE of +0.13%. Regarding short-term risk, HCM is more volatile compared to DRRX. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check DRRX's competition here
HCM vs JUPW Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, HCM is priced at $12.51, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas JUPW's P/E ratio is -2.41. In terms of profitability, HCM's ROE is +0.41%, compared to JUPW's ROE of -1.94%. Regarding short-term risk, HCM is less volatile compared to JUPW. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check JUPW's competition here
HCM vs IXHL Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, IXHL has a market cap of 45.5M. Regarding current trading prices, HCM is priced at $12.51, while IXHL trades at $3.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas IXHL's P/E ratio is -0.18. In terms of profitability, HCM's ROE is +0.41%, compared to IXHL's ROE of -1.99%. Regarding short-term risk, HCM is less volatile compared to IXHL. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check IXHL's competition here
HCM vs INCR Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, INCR has a market cap of 44.8M. Regarding current trading prices, HCM is priced at $12.51, while INCR trades at $0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas INCR's P/E ratio is -3.57. In terms of profitability, HCM's ROE is +0.41%, compared to INCR's ROE of -0.09%. Regarding short-term risk, HCM is less volatile compared to INCR. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check INCR's competition here
HCM vs ZYBT Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, ZYBT has a market cap of 43.6M. Regarding current trading prices, HCM is priced at $12.51, while ZYBT trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas ZYBT's P/E ratio is -4.19. In terms of profitability, HCM's ROE is +0.41%, compared to ZYBT's ROE of -0.26%. Regarding short-term risk, HCM is less volatile compared to ZYBT. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check ZYBT's competition here
HCM vs QLI Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, HCM is priced at $12.51, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas QLI's P/E ratio is -4.92. In terms of profitability, HCM's ROE is +0.41%, compared to QLI's ROE of -0.16%. Regarding short-term risk, HCM is more volatile compared to QLI. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check QLI's competition here
HCM vs SCYX Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, SCYX has a market cap of 37.3M. Regarding current trading prices, HCM is priced at $12.51, while SCYX trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas SCYX's P/E ratio is -1.54. In terms of profitability, HCM's ROE is +0.41%, compared to SCYX's ROE of -0.57%. Regarding short-term risk, HCM is less volatile compared to SCYX. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check SCYX's competition here
HCM vs RMTI Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, RMTI has a market cap of 31.3M. Regarding current trading prices, HCM is priced at $12.51, while RMTI trades at $0.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas RMTI's P/E ratio is -5.28. In terms of profitability, HCM's ROE is +0.41%, compared to RMTI's ROE of -45.88%. Regarding short-term risk, HCM is less volatile compared to RMTI. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check RMTI's competition here
HCM vs HEXO Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, HCM is priced at $12.51, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas HEXO's P/E ratio is -0.26. In terms of profitability, HCM's ROE is +0.41%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, HCM is less volatile compared to HEXO. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check HEXO's competition here
HCM vs QNTM Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, QNTM has a market cap of 30.6M. Regarding current trading prices, HCM is priced at $12.51, while QNTM trades at $6.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas QNTM's P/E ratio is -0.88. In terms of profitability, HCM's ROE is +0.41%, compared to QNTM's ROE of -6.22%. Regarding short-term risk, HCM is less volatile compared to QNTM. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check QNTM's competition here
HCM vs TXMD Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, TXMD has a market cap of 23.6M. Regarding current trading prices, HCM is priced at $12.51, while TXMD trades at $2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas TXMD's P/E ratio is 204.00. In terms of profitability, HCM's ROE is +0.41%, compared to TXMD's ROE of +0.01%. Regarding short-term risk, HCM is less volatile compared to TXMD. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check TXMD's competition here
HCM vs CYTH Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, HCM is priced at $12.51, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas CYTH's P/E ratio is -0.80. In terms of profitability, HCM's ROE is +0.41%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, HCM is more volatile compared to CYTH. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check CYTH's competition here
HCM vs EVOK Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, HCM is priced at $12.51, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas EVOK's P/E ratio is -7.97. In terms of profitability, HCM's ROE is +0.41%, compared to EVOK's ROE of -1.01%. Regarding short-term risk, HCM is more volatile compared to EVOK. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check EVOK's competition here
HCM vs AYTU Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, AYTU has a market cap of 17.7M. Regarding current trading prices, HCM is priced at $12.51, while AYTU trades at $2.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas AYTU's P/E ratio is -0.48. In terms of profitability, HCM's ROE is +0.41%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, HCM is less volatile compared to AYTU. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check AYTU's competition here
HCM vs TLPH Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, TLPH has a market cap of 17.4M. Regarding current trading prices, HCM is priced at $12.51, while TLPH trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas TLPH's P/E ratio is -2.49. In terms of profitability, HCM's ROE is +0.41%, compared to TLPH's ROE of -0.93%. Regarding short-term risk, HCM is less volatile compared to TLPH. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check TLPH's competition here
HCM vs ACRX Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, HCM is priced at $12.51, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas ACRX's P/E ratio is -0.31. In terms of profitability, HCM's ROE is +0.41%, compared to ACRX's ROE of -0.93%. Regarding short-term risk, HCM is less volatile compared to ACRX. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check ACRX's competition here
HCM vs AGRX Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, HCM is priced at $12.51, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas AGRX's P/E ratio is -0.89. In terms of profitability, HCM's ROE is +0.41%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, HCM is less volatile compared to AGRX. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check AGRX's competition here
HCM vs BFRI Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, BFRI has a market cap of 9.8M. Regarding current trading prices, HCM is priced at $12.51, while BFRI trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas BFRI's P/E ratio is -0.78. In terms of profitability, HCM's ROE is +0.41%, compared to BFRI's ROE of -4.77%. Regarding short-term risk, HCM is less volatile compared to BFRI. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check BFRI's competition here
HCM vs COSM Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, COSM has a market cap of 9.1M. Regarding current trading prices, HCM is priced at $12.51, while COSM trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas COSM's P/E ratio is -0.48. In terms of profitability, HCM's ROE is +0.41%, compared to COSM's ROE of -0.82%. Regarding short-term risk, HCM is less volatile compared to COSM. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check COSM's competition here
HCM vs NLTX Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, HCM is priced at $12.51, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas NLTX's P/E ratio is -0.28. In terms of profitability, HCM's ROE is +0.41%, compared to NLTX's ROE of -0.38%. Regarding short-term risk, HCM is less volatile compared to NLTX. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check NLTX's competition here
HCM vs YCBD Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, YCBD has a market cap of 7.9M. Regarding current trading prices, HCM is priced at $12.51, while YCBD trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas YCBD's P/E ratio is 1.25. In terms of profitability, HCM's ROE is +0.41%, compared to YCBD's ROE of -0.38%. Regarding short-term risk, HCM is less volatile compared to YCBD. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check YCBD's competition here
HCM vs LCI Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, HCM is priced at $12.51, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas LCI's P/E ratio is -0.04. In terms of profitability, HCM's ROE is +0.41%, compared to LCI's ROE of +1.66%. Regarding short-term risk, HCM is less volatile compared to LCI. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check LCI's competition here
HCM vs BGXX Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, BGXX has a market cap of 7.3M. Regarding current trading prices, HCM is priced at $12.51, while BGXX trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas BGXX's P/E ratio is -0.76. In terms of profitability, HCM's ROE is +0.41%, compared to BGXX's ROE of -1.16%. Regarding short-term risk, HCM is more volatile compared to BGXX. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check BGXX's competition here
HCM vs ADMP Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, HCM is priced at $12.51, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas ADMP's P/E ratio is -0.08. In terms of profitability, HCM's ROE is +0.41%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, HCM is less volatile compared to ADMP. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check ADMP's competition here
HCM vs EGRX Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, EGRX has a market cap of 4.9M. Regarding current trading prices, HCM is priced at $12.51, while EGRX trades at $0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas EGRX's P/E ratio is 5.36. In terms of profitability, HCM's ROE is +0.41%, compared to EGRX's ROE of +0.17%. Regarding short-term risk, HCM is less volatile compared to EGRX. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check EGRX's competition here
HCM vs MNK Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, HCM is priced at $12.51, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas MNK's P/E ratio is -0.44. In terms of profitability, HCM's ROE is +0.41%, compared to MNK's ROE of -0.26%. Regarding short-term risk, HCM is less volatile compared to MNK. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check MNK's competition here
HCM vs GELS Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, GELS has a market cap of 4.3M. Regarding current trading prices, HCM is priced at $12.51, while GELS trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas GELS's P/E ratio is -0.90. In terms of profitability, HCM's ROE is +0.41%, compared to GELS's ROE of -0.43%. Regarding short-term risk, HCM is less volatile compared to GELS. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check GELS's competition here
HCM vs FLGC Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, HCM is priced at $12.51, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas FLGC's P/E ratio is -0.19. In terms of profitability, HCM's ROE is +0.41%, compared to FLGC's ROE of -0.08%. Regarding short-term risk, HCM is less volatile compared to FLGC. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check FLGC's competition here
HCM vs GHSI Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, GHSI has a market cap of 4.2M. Regarding current trading prices, HCM is priced at $12.51, while GHSI trades at $3.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas GHSI's P/E ratio is -0.79. In terms of profitability, HCM's ROE is +0.41%, compared to GHSI's ROE of +0.01%. Regarding short-term risk, HCM is more volatile compared to GHSI. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check GHSI's competition here
HCM vs CPHI Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, CPHI has a market cap of 3.4M. Regarding current trading prices, HCM is priced at $12.51, while CPHI trades at $1.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas CPHI's P/E ratio is -1.30. In terms of profitability, HCM's ROE is +0.41%, compared to CPHI's ROE of -0.00%. Regarding short-term risk, HCM is less volatile compared to CPHI. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check CPHI's competition here
HCM vs RDHL Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, RDHL has a market cap of 3.2M. Regarding current trading prices, HCM is priced at $12.51, while RDHL trades at $1.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas RDHL's P/E ratio is N/A. In terms of profitability, HCM's ROE is +0.41%, compared to RDHL's ROE of +2.91%. Regarding short-term risk, HCM is less volatile compared to RDHL. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check RDHL's competition here
HCM vs PLXP Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, HCM is priced at $12.51, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas PLXP's P/E ratio is -0.22. In terms of profitability, HCM's ROE is +0.41%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, HCM is less volatile compared to PLXP. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check PLXP's competition here
HCM vs ATNX Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, HCM is priced at $12.51, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas ATNX's P/E ratio is -0.02. In terms of profitability, HCM's ROE is +0.41%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, HCM is more volatile compared to ATNX. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check ATNX's competition here
HCM vs PROCW Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, HCM is priced at $12.51, while PROCW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas PROCW's P/E ratio is N/A. In terms of profitability, HCM's ROE is +0.41%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, HCM is more volatile compared to PROCW. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check PROCW's competition here
HCM vs SNOA Comparison May 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, SNOA has a market cap of 1.9M. Regarding current trading prices, HCM is priced at $12.51, while SNOA trades at $1.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.72, whereas SNOA's P/E ratio is -0.56. In terms of profitability, HCM's ROE is +0.41%, compared to SNOA's ROE of -0.86%. Regarding short-term risk, HCM is less volatile compared to SNOA. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check SNOA's competition here